Skip to main content
Clinical Trials/NCT03381872
NCT03381872
Active, not recruiting
Not Applicable

Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)

Samsung Medical Center1 site in 1 country1,639 target enrollmentMay 10, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Samsung Medical Center
Enrollment
1639
Locations
1
Primary Endpoint
Target vessel Failure
Status
Active, not recruiting
Last Updated
8 months ago

Overview

Brief Summary

The aim of the study is to compare clinical outcomes between intravascular imaging-guided versus angiography-guided percutaneous coronary intervention (PCI) in complex lesions.

Detailed Description

After introduction of the 2nd generation drug-eluting stents (DES), the rates of device-related failure or target lesion failure such as restenosis and stent thrombosis has been markedly decreased, compared with the era of bare metal stents or 1st generation DES. Nevertheless, patients undergoing percutaneous coronary intervention (PCI) for complex lesions, for example, chronic total occlusion (CTO), left main disease, true bifurcation lesion, long lesion, multi-vessel PCI, multiple overlapping stents, or severely calcified lesions have significantly worse clinical outcomes than those with non-complex lesions. During the PCI procedure, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on preintervention lesion characteristics, including vulnerable plaques, lesion severity, length, and morphology; on postintervention optimal stent implantation for stent expansion, extension, and apposition; and on possible complications after stent implantation. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial (RCT) and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the RCTs were limited with small sample size and dealt with very selected lesion subsets such as CTO or long lesion. Moreover, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Meanwhile, appropriate imaging modality may differ according to patient and lesion characteristics. One of the ways to maximize the advantage of intravascular imaging is choice of intravascular imaging devices by the operator's discretion. Therefore, the current RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) is designed to investigate whether PCI under guidance of intravascular imaging devices (IVUS or OCT) chosen by operators would improve clinical outcomes compared with angiography-guided PCI in patients with complex lesions.

Registry
clinicaltrials.gov
Start Date
May 10, 2018
End Date
December 31, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joo-Yong Hahn

Professor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

  • Subject age ≥19 years old
  • Coronary artery disease requiring PCI
  • Patients with complex lesion
  • True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
  • Chronic total occlusion (≥3 months) as target lesion
  • Unprotected LM disease PCI (LM ostium, body, distal LM bifurcation including non-true bifurcation)
  • Long coronary lesions (implanted stent ≥38 mm in length)
  • Multi-vessel PCI (≥2 vessels treated at one PCI session)
  • Multiple stents needed (≥3 more stent per patient)
  • In-stent restenosis lesion as target lesion

Exclusion Criteria

  • Target lesions not amenable for PCI by operators' decision
  • Cardiogenic shock (Killip class IV) at presentation
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol.

Outcomes

Primary Outcomes

Target vessel Failure

Time Frame: 1-year after last patient enrollment

A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization

Secondary Outcomes

  • Target vessel failure without procedure-related MI(4 years after last patient enrollment)
  • Cardiac death or target-vessel related MI(1-year after last patient enrollment)
  • All-cause death(4 years after last patient enrollment)
  • Cardiac death(4 years after last patient enrollment)
  • Target vessel MI with procedure-related MI(4 years after last patient enrollment)
  • Target vessel MI without procedure-related MI(4 years after last patient enrollment)
  • Any MI with procedure-related MI(4 years after last patient enrollment)
  • Any MI without procedure-related MI(4 years after last patient enrollment)
  • Non-target vessel related MI(4 years after last patient enrollment)
  • Target lesion revascularization(4 years after last patient enrollment)
  • Target vessel revascularization(4 years after last patient enrollment)
  • Any revascularization(4 years after last patient enrollment)
  • Stent thrombosis(4 years after last patient enrollment)
  • Incidence of contrast-induced nephropathy(48-72 hours after index procedure)
  • Total amount of contrast use(Immediate after index procedure)
  • Total procedure time(Immediate after index procedure)
  • Total medical cost(1-year after last patient enrollment)
  • Target vessel Failure(4 years after last patient enrollment)
  • Bleeding (BARC definition)(4 years after last patient enrollment)
  • Bleeding (TIMI definition)(4 years after last patient enrollment)

Study Sites (1)

Loading locations...

Similar Trials